Vcanbio Cell & Gene Engineering Executive and Leadership Team

Hongqi Wang, the Vice Chairman & Chief Executive Officer at Vcanbio Cell & Gene Engineering, directs the overarching corporate strategy and long-term vision for precision medicine. Overseeing the integration of cell testing, preparation, and storage, the Vice Chairman & Chief Executive Officer ensures alignment across all global subsidiaries. This leadership role involves managing the expansion of the precision medical industry platform to enhance life science advancements. By optimizing operational efficiency, Hongqi Wang directly impacts the company's ability to provide comprehensive health management services. The Vice Chairman & Chief Executive Officer maintains rigorous oversight of the 600645 stock performance while driving North American and Asian market initiatives. Through strategic resource allocation, Wang secures the financial stability necessary for sustained innovation in cell and gene engineering, ultimately positioning the organization as a leader in the global healthcare sector.

Zhang Yu, the Co-Chief Executive Officer at Vcanbio Cell & Gene Engineering, manages the execution of precision diagnosis and cell therapy business units. Coordinating with the Board, the Co-Chief Executive Officer architects the operational framework for in vitro diagnostic materials and clinical applications. This leadership role involves scaling the company's health management services to meet diverse patient needs across international markets. By streamlining the transition from laboratory research to clinical practice, Zhang Yu directly impacts the efficacy of stem cell and immune cell therapies. The Co-Chief Executive Officer monitors the competitive landscape to ensure the company maintains a technological edge in the precision medicine sector. Through the implementation of standardized quality control protocols, Yu drives operational excellence across all regional facilities. This focus on precision and safety supports the broader mission of enhancing global health standards through advanced biotechnology.

Sun Yan, the President at Vcanbio Cell & Gene Engineering, manages the day-to-day operations of the precision prevention and health management divisions. Executing the company's growth strategy, the President coordinates cross-departmental efforts to scale the delivery of cell-based health services. This leadership role involves optimizing the supply chain for diagnostic materials and ensuring the seamless operation of storage facilities. By fostering internal collaboration, Sun Yan directly impacts the efficiency of the company's precision medical platform. The President monitors performance metrics to ensure that all business units meet the high standards required for life-cycle health management. Through the implementation of scalable operational models, Yan drives expansion across diverse geographic regions. This focus on operational agility allows the organization to adapt quickly to market shifts, ensuring that the company remains at the forefront of the precision medicine industry.

Zhang Wei, the President & Researcher at Vcanbio Cell & Gene Engineering, leads the scientific research and development initiatives focused on next-generation cell therapy. Architecting the laboratory infrastructure, the President & Researcher drives the innovation pipeline for new diagnostic tools and therapeutic breakthroughs. This leadership role involves translating complex scientific data into actionable clinical applications that benefit humanity. By spearheading internal research projects, Zhang Wei directly impacts the company's ability to pioneer advancements in life sciences. The President & Researcher collaborates with the medical team to ensure that scientific discoveries align with the company's precision medicine goals. Through the continuous exploration of stem cell and immune cell potential, Wei secures the company's position as a leader in biotechnology. This dedication to scientific excellence supports the broader mission of providing comprehensive health management services that improve global health outcomes.

Hongtao Li, the Chief Medical Officer at Vcanbio Cell & Gene Engineering, oversees the clinical development and safety protocols for all stem cell and immune cell therapies. Directing the medical research team, the Chief Medical Officer ensures compliance with international health standards and regulatory requirements. This leadership role involves evaluating the clinical efficacy of new diagnostic materials and therapeutic applications. By bridging the gap between scientific discovery and patient care, Hongtao Li directly impacts the success of the company's precision medicine initiatives. The Chief Medical Officer collaborates with external research institutions to advance the understanding of life sciences. Through the rigorous assessment of clinical trial data, Li mitigates risks and optimizes treatment outcomes for patients. This commitment to medical integrity and innovation strengthens the company's reputation as a provider of high-quality, life-cycle health management services across global markets.